Treating Aggressive Brain Tumors With Less Side Effects
Biologics drugs are not designed for the treatment of brain diseases. Only a margin crosses the brain blood barrier (below 1%). Biological drugs such as antibodies are designed for long systemic retention, which means that once they are applied in the brain, they start accumulating in the body, which can lead to severe side effects. This is why neurosurgeons have started applying drugs locally, directly into the affects brain regions for various disease indications such as Parkinsons Disease or brain cancer.
InCephalo develops local antibody and cytokine treatments for neurologic diseases.
The startup’s unique and proprietary compartment locked technology, also called CLocked, retains locally applied biologics in the central nervous system (CNS). These biological drugs have two properties:
- they stay in the desired compartment, and
- if they leak, they are rapidly degraded.
The combination of both properties will significantly reduce the drug’s overall exposure to the body and allows for a higher local dosing window with reduced adverse side effects in other parts of the body.
InCephalo has a preclinical candidate for Glioblastoma, an aggressive brain tumor. Finding new therapies for individuals with hard to treat CNS diseases will significantly impact patients and their families lives.